RE104 Sikkerheds- og Effektivitetsundersøgelse ved Generaliseret Angstlidelse
En randomiseret, dobbeltblind, placebokontrolleret undersøgelse, der evaluerer sikkerheden og effekten af RE104 til injektion i behandlingen af generaliseret angstlidelse
The purpose of this study is to determine if treatment with a single and/or repeat dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Mark Pollack Chief Medical Officer, M.D.
- Telefonnummer: 1-888-880-REUN
- E-mail: info@reunionneuro.com
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35209
- Rekruttering
- University of Alabama (UAB) Clinical Research Unit (CRU)
-
Kontakt:
- Seher Premani
- Telefonnummer: spremani@uab.edu
- E-mail: spremani@uab.edu
-
-
Arizona
-
Gilbert, Arizona, Forenede Stater, 85234
- Rekruttering
- Lighthouse Psychiatry
-
Kontakt:
- Matt Longson
- Telefonnummer: 435-268-5800
- E-mail: Contact@neosciclinicalresearch.com
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72211
- Rekruttering
- Preferred Research Partners, Inc.
-
Kontakt:
- Stacy Tierney
- Telefonnummer: 111 501-553-9987
- E-mail: stierney@preferredresearchpartners.com
-
-
California
-
Garden Grove, California, Forenede Stater, 92845
- Rekruttering
- Collaborative Neuroscience Research, LLC
-
Kontakt:
- CNS Outreach Department
- Telefonnummer: 844-424-9494
- E-mail: cns.outreach@cenexel.com
-
La Jolla, California, Forenede Stater, 92037
- Rekruttering
- Kadima Neuropsychiatry Institute
-
Kontakt:
- Angelica Lu
- Telefonnummer: 858-775-2053
- E-mail: angelical@kadimanp.com
-
San Francisco, California, Forenede Stater, 94114
- Rekruttering
- Open Mind Therapeutics
-
Kontakt:
- Victoria Vega
- Telefonnummer: 415-906-7399
- E-mail: victoria@openmindcollective.org
-
Santa Monica, California, Forenede Stater, 90404
- Rekruttering
- TRIP Clinic at Psychedelic Science Institute
-
Kontakt:
- Ashley Ramos
- E-mail: trialadmin@psychedlicsci.com
-
-
Florida
-
Lauderhill, Florida, Forenede Stater, 33319
- Rekruttering
- Innovative Clinical Research, Inc.
-
Kontakt:
- Melissa Rodco
- Telefonnummer: 305-722-8444
- E-mail: mrodco@segaltrials.com
-
Tampa, Florida, Forenede Stater, 33613
- Rekruttering
- University of South Florida
-
Kontakt:
- Genesis Estramera
- Telefonnummer: 813-974-1404
- E-mail: gestramera@usf.edu
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30331
- Rekruttering
- Atlanta Center for Medical Research
-
Kontakt:
- Amber Tannahill
- Telefonnummer: 404-881-5800
- E-mail: a.tannahill@cenexel.com
-
Decatur, Georgia, Forenede Stater, 30030
- Rekruttering
- CenExel iResearch, LLC
-
Kontakt:
- Michael Mahaffrey
- E-mail: m.mahaffrey@cenexel.com
-
Norcross, Georgia, Forenede Stater, 30092
- Rekruttering
- Evergreen Clinical Trials
-
Kontakt:
- Stephen Wheeler
- Telefonnummer: 943-230-1385
- E-mail: stephen@evergreenstrials.com
-
Savannah, Georgia, Forenede Stater, 31405
- Rekruttering
- CenExel iResearch, LLC
-
Kontakt:
- Michelle Lagares
- Telefonnummer: 912-744-0800
- E-mail: M.Lagares@CenExel.com
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60640
- Rekruttering
- Uptown Research Institute
-
Kontakt:
- Deborah Jones-Miller
- Telefonnummer: 117 773-989-8313
- E-mail: Djones-miller@uptownresearch.com
-
-
Michigan
-
Novi, Michigan, Forenede Stater, 48377
- Rekruttering
- Henry Ford Medical Center - Columbus
-
Kontakt:
- Madeline Bross
- Telefonnummer: 248-344-7366
- E-mail: mbross1@hfhs.org
-
-
Missouri
-
Saint Charles, Missouri, Forenede Stater, 63304
- Rekruttering
- Midwest Research Group
-
Kontakt:
- Lindsay vanWinkle
- Telefonnummer: 3 636-946-8032
- E-mail: lvanwinkle@midwestresearchgroup.com
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 14624
- Rekruttering
- UNM Research Program Psychedelic Therapies
-
Kontakt:
- Hector Garcia
- Telefonnummer: 505-675-0582
- E-mail: hecgarcia@salud.unm.edu
-
-
New York
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- NYU-H+C Clinical and Translational Science Institute
-
Kontakt:
- Jillian Kelly
- Telefonnummer: 212-404-7764
- E-mail: Jillian.kelly@nyulangone.org
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- Rekruttering
- University of North Carolina at Chapel Hill
-
Kontakt:
- Julia Hoffman
- E-mail: julia_hoffmann1@med.unc.edu
-
-
Ohio
-
North Canton, Ohio, Forenede Stater, 44720
- Rekruttering
- Neuro-Behavioral Clinical Research, Inc.
-
Kontakt:
- Crystal Blackford
- Telefonnummer: 330-493-1118
- E-mail: cblackford@nb-cr.com
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97210
- Rekruttering
- Summit Headlands LLC
-
Kontakt:
- Tyler Leecing
- E-mail: tyler.leecing@summitnetwork.com
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- University of Pennsylvania
-
Kontakt:
- Erin Blase
- Telefonnummer: 215-746-6419
- E-mail: erin.blase@pennmedicine.upenn.edu
-
West Chester, Pennsylvania, Forenede Stater, 19380
- Trukket tilbage
- Suburban Research Associates
-
-
Texas
-
Austin, Texas, Forenede Stater, 78737
- Rekruttering
- Austin Clinical Trial Partners
-
Kontakt:
- Kara Chilek
- Telefonnummer: 512-521-0595
- E-mail: studyinfo@austinCTP.com
-
Austin, Texas, Forenede Stater, 78759
- Rekruttering
- BioBehavioral Research Austion
-
Kontakt:
- Tracie Wesson
- Telefonnummer: 402-934-0044
- E-mail: tracie.wesson@qcrnetwork.com
-
Plano, Texas, Forenede Stater, 75093
- Rekruttering
- Aim Trials, LLC
-
Kontakt:
- Sonia Prashar
- Telefonnummer: 214-856-2778
- E-mail: sonia.prashar@aimtrials.com
-
-
Utah
-
Draper, Utah, Forenede Stater, 84020
- Rekruttering
- Cedar Clinical Research
-
Kontakt:
- Jane Bjorklund
- Telefonnummer: 801-369-4219
- E-mail: jane.bjorklund@numinusnetwork.com
-
Orem, Utah, Forenede Stater, 84058
- Rekruttering
- Inner Space State Street
-
Kontakt:
- Janet Jimenez
- Telefonnummer: 801-871-5516
- E-mail: apply@innerspaceresearch.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Has Generalized Anxiety Disorder as defined by DSM-5-TR
- If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant.
- Is willing and able to comply with the conditions and requirements of the study
Exclusion Criteria:
- Has a significant risk of suicide
- Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
- Has other concurrent psychiatric disorders that is the primary disorder.
- Has other medically significant conditions rendering unsuitability for the study
- Has used or will need to use prohibited medications or therapies
- Has a known sensitivity or intolerance to study intervention or potential rescue medications
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
A single subcutaneous injection of 0.9% sodium chloride for injection per dosing session |
Single-dose (Part A) or Repeat-dose (Part B), subcutaneous injection(s) of 0.9% sodium chloride for injection |
|
Eksperimentel: 30 mg RE104
A single subcutaneous injection of 30 mg RE104 for Injection per dosing session |
Single dose (Part A) or Repeat-dose (Part B), subcutaneous injection(s) of RE104 for Injection |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
RE104 when administered as a single 30 mg dose or as two 30 mg doses 3 weeks apart versus placebo change from Baseline at Week 4 in Hamilton Anxiety Rating Scale (HAM-A) total score
Tidsramme: Week 4
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Week 4
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
RE104 versus placebo changes in total score from baseline in Hamilton Anxiety Rating Scale (HAM-A)
Tidsramme: Weeks 1, 2, 8 and 12
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Weeks 1, 2, 8 and 12
|
|
RE104 versus placebo percentage of participants with HAM-A response (≥50% reduction in score from Baseline)
Tidsramme: Weeks 1, 2, 4, 8 and 12
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Weeks 1, 2, 4, 8 and 12
|
|
RE104 versus placebo percentage of participants with HAM-A remission (total score ≤7)
Tidsramme: Day 1 and Weeks 1, 2, 4, 8 and 12
|
The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety. |
Day 1 and Weeks 1, 2, 4, 8 and 12
|
|
RE104 versus placebo change from Baseline at Weeks 1, 2, 4, 8, and 12 in Hospital Anxiety and Depression Scale (HADS) depression subscore
Tidsramme: Weeks 1, 2, 4, 8 and 12
|
The Hospital Anxiety and Depression Scale (HADS) is a self-reported scale measure the severity of depression and anxiety in patients with comorbid medical conditions. The scale consists of 14 items (7 for anxiety and 7 for depression), with a score ranging between 0 and 21 for the anxiety and depression subscales. |
Weeks 1, 2, 4, 8 and 12
|
|
RE104 versus placebo incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness.
Tidsramme: From dosing through study completion (post-dose follow-up is for 12 weeks)
|
A treatment-emergent adverse event (TEAE) is defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a study drug. |
From dosing through study completion (post-dose follow-up is for 12 weeks)
|
|
RE104 versus placebo change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) (Part B only)
Tidsramme: Weeks 1, 2, 4, 8, and 12
|
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression. |
Weeks 1, 2, 4, 8, and 12
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Mark Pollack, M.D., Reunion Neuroscience Inc
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- RE104-203-GAD
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .